Ascenta Capital

Ascenta Capital backs biotech companies building multi-asset platforms to translate science into therapies. They invest early and provide strategic and operational support across clinical, regulatory, manufacturing, and capital planning. The firm focuses on multi-product platform investments and collaborates with management to advance from preclinical science to early human data. Their approach combines concentrated investments with hands-on guidance to de-risk development and scale platforms. Based in New York, the firm targets biopharma companies creating medicines with broad platform potential.